Biogen to buy RayThera for up to USD 1 billion

Biogen Inc.

Biogen Inc.

BIIB

0.00
  • Biogen agreed to buy RayThera for up to USD 1 billion, combining an upfront payment with mostly clinical and regulatory milestone payments.
  • RayThera is a privately held immunology drug developer focused on small-molecule anti-inflammatory therapies for immune-mediated diseases.
  • The lead candidate is expected to enter Phase 1 in early Q3 2026.
  • Closing is targeted for Q3 2026, subject to customary conditions and required approvals.
  • Biogen would take over development, manufacturing, and global commercialization once the deal closes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606171859PRIMZONEFULLFEED9748927) on June 17, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.